Boardroom Media (CEO News)
At CEO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Beijing based CEO’ operating in the Biotechnology space. If you think a CEO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Liangzhi Xie
President and CEO of Sino Biological
Dr. Xie obtained his doctor degree from the Biotechnology Process Engineering Center at Massachusetts Institute of Technology under the supervision of Prof. Daniel I.C. Wang. At MIT, Dr. Xie developed a stoichiometric model to optimize the design of mammalian cell culture medium and the control of the dynamic culture environment. In 1994, he was able to achieve a record cell density of 1.7 x 107 cells/ml and a record antibody titer of 2.4 gram/L. He then worked on viral vaccine process development and cGMP manufacturing for three US FDA approved products (Varicella® , Zostervax® , and ProQuad® ) at Merck Research Laboratory, Merck & Company. He also led the cell culture and viral vaccine process development and cGMP clinical production for Merck’s adenovirus based HIV vaccine and helped to develop by far the largest scale (2000L) of human viral vaccine process under serum-free condition in stirred-tank bioreactors. He is also the director and professor at the Cell Culture R&D center at the Peking Union Medical College since 2002.
Follow Liangzhi Xie:
About Sino Biological, Sinocelltech: Sino Biological is a specialist provider of protein, antibody and gene products.
Ruiqiang Li
Founder & CEO of Novogene
Dr. Ruiqiang Li, is widely recognized as one of the world’s leading experts in genomics and bioinformatics, owning 17 patents and has authored over 100 publications that have been cited more than 42,000 times. Best known for developing the software SOAP (Short Oligonucleotide Analysis Package) for ultra-fast sequence mapping, variation detection, and de novo genome assembly, Dr. Li has focused the company on being a full-service provider, performing NGS services and providing bioinformatic analysis to fully empower and enable our customers to move forward rapidly and effectively in their scientific endeavors.
Follow Ruiqiang Li:
About Novogene: Novogene is a provider of genomic services and solutions with cutting edge NGS.
Yinxiang Wang
CEO and Chairman of Jacobio Pharmaceuticals
Yinxiang WANG graduated from the University of Arkansas for Medical Sciences in 1999, and served as a postdoctoral research fellow at the Department of Molecular Biophysics and Biochemistry of Yale University from 1999 to 2003.He returned to China in 2003 and founded Betta Pharmaceuticals. As the CEO and CSO (2003-2017) of Betta Pharmaceutiacals, YinxiangWang headed the research team, which developed Icotinib Hydrochloride (Conmana), a new molecular entity (NME) for lung cancer. This novel drug is the first small molecule anticancer drug that is completely developed in China and approved by CFDA in 2011. The project won the 1st prize of National Science and Technology Award, the gold medal of WIPO-SIPO Award in 2012 and 2014, and the 1st prize of Science and Technology Award in Zhejiang province. Betta went public at Shenzhen Exchange in 2016.Betta formed JV with Amgen (Amgen-Betta Pharmaceuticals) in 2013 and YinxiangWang served as GM (2013-2017).In 2015, he founded Jacobio Pharmaceuticals and ETown-Jacobio Biocapital in Beijing and serving as the Chairman. Jacobio is focused on innovative drug R&D, especially First-in-Class drugs, and ETown-Jacobio Biocapital as an angel fund to invest early stage R&D of innovative drugs. YinxiangWang is the Chairman, New Drug R&D Committee of China.Pharmaceutical Innovation and Research Development Association (PHIRDA); Associate Chairman,Oncology Drug Clinical Research Committee of Chinese Pharmaceutical Association.YinxiangWang was selected to be the national “Recruitment Program of Global Experts (1000-experts plan)”in 2012.YinxiangWang was selected to be the winner of 2017 CABS K.Fong Award in Life Sciences.
Follow Yinxiang Wang:
About Jacobio Pharmaceuticals: Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company focusing on the development of innovative oncology and other therapies.
Du Bo
Co-Founder and CEO of GeneCast Biotechnology
Du Bo, Co-founder and CEO of Genecast (Beijing) Biotechnology Co., also a member of the Biotech Diagnosis Branch of China Medicinal Biotech Association. As one of the earliest developers to enter the field of NGS in China, Du Bo also co-founded China’s first NGS reagent manufacturer, Quest Genomics (Nanjing) Co., Ltd. Du Bo has accumulated rich experience in investment, pharmaceuticals, and second-generation sequencing, which renders him deep insights in corporate strategic development and management. He has frequently been invited to deliver speeches at conferences in biomedical field, and has won numerous awards, including the prestigious China Pharmaceutical Association’s Technology Progress Award. Du Bo graduated from the department of biology of Peking University.
Follow Du Bo:
About GeneCast Biotechnology: GeneCast Biotechnology is dedicated to improving cancer treatment through precision cancer diagnostics and companion diagnostics.
Xing Li
Founder and CEO of Deep Intelligent Pharma
With over 12 years’experience in drug development in Pfizer, Sanofi, and Johnson & Johnson, she founded the startup in October 2017, aiming to utilize most advanced AI technologies to empower and accelerate the whole drug discovery & development process. In Johnson & Johnson, she built a team of 31 staff from zero and implemented the first AI program in Johnson & Johnson Asia – regulatory document machine translation system – successfully. Xing got her master’s degree from Peking University Health Science Center in pharmaceutics.
Follow Xing Li:
About Deep Intelligent Pharma: Deep Intelligent Pharma is a Beijing based Healthcare company.
Daixing Zhou
CEO of Berry Genomics
Dr. Daixing Zhou is the Chief Executive Officer of Berry Genomics Co., Ltd, located in Beijing, China. Prior to founding Berry Genomics, Dr. Zhou held multiple positions in the next generation sequencing industry, including the Leader of Market Development at Life Technologies Corp., the Head of Sequencing Sales at Illumina-Asia Pacific Japan, and the Director of Bioinformatics at Solexa Inc/Lynx Therapeutics. Dr. Zhou earned his Ph.D. from University of Maryland at Baltimore, and completed his postdoctoral training at Duke University.
Follow Daixing Zhou:
About Berry Genomics: Berry Genomics is a company specializing in developing and commercializing technologies for life sciences and clinical applications.
Yeqing Zhu
CEO of New Horizon Health
Follow Yeqing Zhu:
About New Horizon Health: New Horizon Health is a bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes.
Wei Dong
CEO of EdiGene
Wei Dong has over 20 years of experience in drug development and corporate management in multinational companies . He holds a Ph.D. from Michigan State University, an MBA from Wharton , and a bachelor’s degree from Peking University. He used to be a senior consultant and manager of Deloitte Consulting, providing overall planning and consulting services for biotech companies and pharmaceutical companies. Formerly Senior Director of Johnson & Johnson Innovation Center, responsible for business operations and project management. He used to be Baxalta (later acquired by Shire , now affiliated to Takeda Pharmaceutical), senior director of clinical development in immunotherapy, and global development leader. He has experience in the development, clinical trials and management of a variety of innovative drugs, including Alzheimer’s disease drug development, cancer vaccine research and development, genetic disease orphan drug research and development.
Follow Wei Dong:
About EdiGene: EdiGene is a biotechnology company that develops genome editing technologies.
He Ting
CEO of Immunochina
He Ting graduated from the Department of Biology in Tsinghua University with a Ph.D. degree, with his research interest in cancer immunology and metastasis during his graduate study. In 2015, Ting established ImmunoChina Pharmaceuticals Co. Ltd. and has worked as the CEO since then. ImmunoChina has received several rounds of investment by venture capitals such as Peter Thiel and Legend Capital, and now it is the leading bio-company focusing on innovative CAR-T therapy in China.
Follow He Ting:
About Immunochina: Immunochina Pharmaceuticals produces cell injections, cell therapy drugs, and other products and provides medical technology development.
Xiaodong Wu
CEO of China Medical Technologies
Follow Xiaodong Wu:
About China Medical Technologies: China Medical Technologies is a medical device company that develops, manufactures products using HIFU for the treatment of solid cancers.
Bob Liu-Bellenchem
Co-founder & CEO of Bellen
Follow Bob Liu-Bellenchem:
About Bellen: A Chinese medical contract research organization.
Wenting Chen
Chairman and CEO of Laviana Pharma
Follow Wenting Chen:
About Laviana Pharma: Laviana Pharmatech specializes in providing process and manufacture outsourcing services for the pharmaceutical industry.
Duojia Feng
CEO of Beijing Tiantan Biological Products
Duojia Feng is CEO at Beijing Tiantan Biological Products.
Follow Duojia Feng:
About Beijing Tiantan Biological Products: Beijing Tiantan Biological Products Corporation Limited specializes on the biopharmaceutical industry.
Depeng Wang
CEO of GrandOmics
As a senior in the field of sequencing, he started the application of Sanger sequencing technology in 2000 and has been engaged in the application of next generation sequencing technology since 2007, including early incubation and promotion of NIPT, PGD/PGS, HLA typing, whole exome sequencing and so on. With the development of third-generation sequencing technology, he started sequencing services based on third-generation sequencing technology in 2012 and initiated and participated in the completion of the first near complete reference Chinese human genome“HuaXia1(HX1)” led by professor Wang kai and Su guohui. Since 2016, he has been engaged in research on Chinese structural variation data and participated in several major research projects based on third-generation sequencing technology.
Follow Depeng Wang:
About GrandOmics: Grandomics provides molecular diagnosis, research, and carrier screening for single gene diseases.
Sharong Li
Founder and CEO of Genedock
Follow Sharong Li:
About Genedock: Genedock is a Healthcare company.
